Cnv-2197944 Industry 2015,Share and Size, Trends and Price, Forecast and Market Analysis to 2022

Hexa Reports

Market Research Reports and Insightful Company Profiles

CNV-2197944 Industry 2015,Share and Size,Trends and

Price,Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different

from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference

between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in

neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain

syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic

neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat

these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical

treatments. However, despite the availability of multiple pain medications only 50% of patients respond

to any given drug and there are numerous the side effects associated particularly with systemically

administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in

terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably

eradicated NP in targeted patient populations, as well as offering an improved safety profile.

CNV-2197944 is a novel therapy being developed by Convergence Pharmaceuticals for the treatment of

chronic pain. It is currently in Phase II of clinical development for both PHN and PDN. The drug was

acquired from GlaxoSmithKline (GSK) in 2010 as part of an agreement in which GSK acquired an 18%

minority equity stake in Convergence Pharmaceuticals. However, as part of the restructuring of

Hexa Reports

Market Research Reports and Insightful Company Profiles

Convergence in 2011, CNV-2197944 was transferred to Calchan Ltd., a sister company of Convergence

Pharmaceuticals, which now holds the...